Brought to you by 
Toray gets rights to Acologix's AC200 for hyperphosphatemia
29 Sep 2009
Executive Summary
Toray Industries has licensed exclusive Japanese rights to Acologix's (developing drug candidates for osteo-renal diseases) AC200, a recombinant protein in preclinical studies for hyperphosphatemia. Acologix originally obtained the exclusive rights to AC200 under a 1999 deal with University College London.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Toray gets rights to Acologix's AC200 for hyperphosphatemia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice